Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248936 · ClinicalTrials.gov registry record · Phase 2
A Study of RO5185426 in Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 374
- Enrollment target
NCT01248936 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 374 participants.
The verdict
NCT01248936, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 374 participants
- Enrollment target
Study Summary
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
Interventions
- DRUG RO5185426
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01248936
The ClinicalTrials.gov registry entry for NCT01248936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 374 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO5185426 is the first listed.
NCT01248936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01248936 about?
NCT01248936 is a clinical study titled "A Study of RO5185426 in Patients With Metastatic Melanoma". This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
What is the current status of trial NCT01248936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 374 participants. The study started on 2010-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01248936?
The interventions under investigation include: RO5185426 (DRUG).
Who is sponsoring clinical trial NCT01248936?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.